Phase 3 Major Depressive Disorder Clinical Trials
33 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 33 trials
Recruiting
Phase 3
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
DepressionDepression - Major Depressive DisorderDepression in Adults+3 more
Cybin IRL Limited330 enrolled67 locationsNCT06793397
Recruiting
Phase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences850 enrolled87 locationsNCT06966401
Recruiting
Phase 3
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Major Depressive Disorder
Cybin IRL Limited220 enrolled47 locationsNCT06564818
Recruiting
Phase 3
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled30 locationsNCT06963021
Recruiting
Phase 3
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Major Depressive Disorder
Neumora Therapeutics, Inc.1,000 enrolled178 locationsNCT06029439
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled42 locationsNCT07076407
Recruiting
Phase 3
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences550 enrolled45 locationsNCT07196501
Recruiting
Phase 3
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Axsome Therapeutics, Inc.508 enrolled13 locationsNCT07484217
Recruiting
Phase 3
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder
Takeda180 enrolled30 locationsNCT07204314
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled74 locationsNCT06058013
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
Major Depressive DisorderTreatment Resistant Depression
Weill Medical College of Cornell University348 enrolled2 locationsNCT04041479
Recruiting
Phase 3
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Major Depressive Disorder
Neumora Therapeutics, Inc.332 enrolled71 locationsNCT06058039
Recruiting
Phase 3
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Major Depressive DisorderBipolar DepressionSchizophrenia and Related Disorders
Dr. Inge Winter1,254 enrolled1 locationNCT05603104
Recruiting
Phase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled10 locationsNCT06911112
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Neurocrine Biosciences200 enrolled18 locationsNCT06786624
Recruiting
Phase 3
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Major Depressive Disorder
Xenon Pharmaceuticals Inc.450 enrolled46 locationsNCT06775379
Recruiting
Phase 3
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Major Depressive DisorderTreatment Resistant Depression
Dr. Inge Winter418 enrolled12 locationsNCT05973851
Recruiting
Phase 2Phase 3
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Suicidal IdeationMajor Depressive DisorderBipolar Disorder+1 more
Michigan State University30 enrolled1 locationNCT06529029
Recruiting
Phase 3
Efficacy of Statins Among Major Depressive Disorder
Major Depressive DisorderMDD
Ain Shams University145 enrolled1 locationNCT06698666